This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Unwanted effects

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • pneumococcal conjugate vaccine (PCV)
    • swelling and redness at the injection site and low grade fever are among the most commonly reported adverse reactions (10–20%)
    • no increased local or systemic reactions have been reported with repeated doses during the primary series, although a higher rate of transient tenderness has been reported after a fourth dose
  • pneumococcal polysaccharide vaccine (PPV)
    • mild soreness and induration at the site of injection lasting one to three days
    • lless commonly, a low grade fever may occur
    • more severe systemic reactions are infrequent. In general, local and systemic reactions are more common in people with higher concentrations of antibodies to pneumococcal polysaccharides

  • confirmed anaphylaxis involving pneumococcal vaccines is rare. Other allergic conditions, such as rashes, may occur more commonly and are not contraindications to further immunisation (1)

Reference:

  1. Immunisation Against Infectious Disease - "The Green Book".Chapter 25 Pneumococcal (April 2019)
  2. Drug and Therapeutics Bulletin (1998); 36 (10): 73-6.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.